For Research Use Only. Not for Human Consumption.
Recorded market$62.83Recorded exact-size market estimate: 62.83 USD for one 10 mg container (6.282538 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$62.00Member price$46.1726.5% lessMembers save $16.66 on this item vs. recorded market
Mitochondria-targeted tetrapeptide for research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 10 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$4.62/mg26.5% less
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:30 UTC. 1 x 10 mg = 10 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| PS Peptides Oct 10, 2026 UTC | One 10 mg container; 64.99 USD | $6.50/mg | powder; publicly listed Selected SKU PSP-SS31-10MG, one bottle, $64.99; publisher AggregateOffer confirms USD; single 10 mg lyophilized vial. Price observation; no COA authentication is implied by inclusion. |
| Peptides Optimized Oct 10, 2026 UTC | One 10 mg container; 38.99 USD | $3.90/mg | powder; publicly listed Default selected 10 mg, explicit single vial USD38.99; current automatic sale price, case-of-ten and multi-buy promotions excluded. Price observation; no COA authentication is implied by inclusion. |
| Sparta Labs Oct 10, 2026 UTC | One 10 mg container; 75.00 USD | $7.50/mg | powder; conflicting: visible in stock, structured offer out of stock Public selected 10 mg single lyophilized vial, USD75. Page says in stock while publisher Offer says OutOfStock; availability conflict flagged. Price observation; no COA authentication is implied by inclusion. |
| Dissolv Labs Oct 10, 2026 UTC | One 10 mg container; 25.00 USD | $2.50/mg | powder; publicly listed Current public automatic sale USD25 for exact 10 mg single sealed lyophilized vial; regular USD50. Price observation; no COA authentication is implied by inclusion. |
| Ascension Peptides Oct 10, 2026 UTC | One 10 mg container; 79.99 USD | $8.00/mg | powder; publicly listed Public10mg singlelyophilized vial $79.99. SupplierTermsconfirmsUnitedStatesdollars. Price observation; no COA authentication is implied by inclusion. |
| Nationwide Peptides Oct 10, 2026 UTC | One 10 mg container; 48.00 USD | $4.80/mg | powder; publicly listed Publisher exact 10 mg ProductOffer USD48; selected SKU ss-31-10mg. Product Storage & Handling tab states lyophilized sealed vial; main price remained stale USD199 from 50 mg, so exact publisher variant quote used; coupon excluded. Price observation; no COA authentication is implied by inclusion. |
| Peptara Labs Oct 10, 2026 UTC | One 10 mg container; 120.00 USD | $12.00/mg | powder; publicly listed Current supplier price page $120 USD per single sealed 10 mg lyophilized vial; includes free preparation supplies; email-signup and bulk tiers excluded. Price observation; no COA authentication is implied by inclusion. |
| Durham Peptides Oct 11, 2026 UTC | One 10 mg container; 89.99 CAD | $6.33/mg | lyophilized powder; In stock Price observation; no COA authentication is implied by inclusion. |
| Peptide Titans Oct 11, 2026 UTC | One 10 mg container; 79.99 USD | $8.00/mg | powder; in stock Only offered strength 10 mg; title/body explicit single lyophilized 10mg vial and public USD Offer79.99 automatic sale100. Basic age/RUO notice left unaccepted; qualified purchaser requirement applies purchasing. No coupon/bundle discount. Price observation; no COA authentication is implied by inclusion. |
| Alpha Strain Peptides Oct 11, 2026 UTC | One 10 mg container; 24.99 GBP | $3.30/mg | powder; in stock Explicit10mgpervial white/offwhite lyophilizedpowder qty1 public24.99GBP. Basicage-only notice left unaccepted; no Terms/profentry. No email10%coupon. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “SS-31 – 10 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/ss-31-10-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/ss-31-10-mg/
A cell-permeable tetrapeptide that concentrates at the inner mitochondrial membrane, used in studies of cardiolipin interaction and mitochondrial function.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
Elamipretide, also called SS-31, is the ingredient in Forzinity, approved for a defined Barth-syndrome population. That narrow approval does not establish general anti-aging use.
SS-31 is a mitochondria-targeted peptide studied under the name elamipretide. Forzinity is a particular pharmaceutical formulation; a vendor’s SS-31 sample is not automatically the approved product.
Mitochondrial function is a broad biological topic. A study of one disorder or model cannot establish treatment of every condition associated with mitochondrial changes.
FDA granted accelerated approval in September 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Approval relied on an intermediate muscle-strength endpoint and requires further confirmation of clinical benefit. The clinical record should be read together with the negative randomized walking and fatigue results, rather than reduced to a blanket proven or unproven label.
| Study and design | Finding | What it does not establish |
|---|---|---|
| FDA review of the Forzinity Barth-syndrome trial
Twelve-participant randomized crossover study followed by an open-label extension Reading scope: Official FDA trial snapshot and clinical-results tables |
The randomized period did not show superiority on the main walking-distance and fatigue endpoints; longer open-label observations showed increased knee-extensor strength. | A tiny rare-disease sample and an uncontrolled extension limit inference; accelerated approval is not confirmation of every claimed clinical benefit. |
| Beneficial effects of SS-31 peptide on cardiac mitochondrial dysfunction in tafazzin knockdown mice.
Tafazzin-knockdown mouse experiments Reading scope: PubMed bibliographic record and abstract |
SS-31 improved selected mitochondrial respiration and supercomplex-organization measures without correcting the measured monolysocardiolipin-to-cardiolipin ratio. | Mechanistic improvement in a mouse model is not evidence of broad rejuvenation or correction of the underlying genetic defect. |
| Mitochondrial protein interaction landscape of SS-31.
Protein-interaction mapping using mitochondrial preparations Reading scope: PubMed bibliographic record and abstract |
The investigators identified interactions with proteins involved in mitochondrial metabolism and energy-related processes. | An interaction map does not establish clinical effectiveness for an unrelated disease or longevity use. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
An intermediate clinical endpoint may support accelerated approval while leaving the ultimate clinical benefit to be confirmed. This distinction should remain visible beside the approved indication.
A positive laboratory respiration measure and a meaningful improvement in daily function are different outcomes. The same applies to changes in muscle strength versus walking distance or fatigue.
The appropriate comparison is the exact product in its studied population. Neither the drug’s approval nor a mechanistic paper authenticates a research vial.
The Forzinity label reports injection-site reactions and hypersensitivity, including serious allergic reactions. Its formulation contains benzyl alcohol and must not be used in neonates.
The approved population and monitoring context do not establish safety in healthy adults seeking enhancement or in other unstudied circumstances.
Separate the randomized crossover period from the open-label extension. Duration, comparator and endpoint differ, so their results cannot be merged into one placebo-controlled effect.
Read approved exposure information in the current product label and clinical context. Animal protocols and general research-vial listings cannot supply an equivalent regimen.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Verify whether documentation identifies elamipretide and the particular formulation, rather than a generic mitochondrial peptide. Sequence and terminal chemistry need an exact match.
Distinguish analytical identity from authenticated Forzinity supply. A certificate cannot transfer the pharmaceutical product’s approval to an independently prepared material.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. Forzinity received a specific accelerated approval in 2025. It is inaccurate to ignore that approval or to expand it into approval of all SS-31 products and uses.
No. The approval rationale instead includes the muscle-strength findings and a requirement to confirm clinical benefit.
No. A mitochondrial mechanism does not establish a human longevity outcome.
This companion to the SS-31 / Elamipretide research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Separate the randomized crossover period from the open-label extension. Duration, comparator and endpoint differ, so their results cannot be merged into one placebo-controlled effect.
Read approved exposure information in the current product label and clinical context. Animal protocols and general research-vial listings cannot supply an equivalent regimen.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.